EMC.V - Emblem Corp.

TSXV - TSXV Delayed Price. Currency in CAD
1.20
-0.02 (-1.64%)
At close: 4:53PM EDT
Stock chart is not supported by your current browser
Previous Close1.22
Open1.24
Bid1.18 x 0
Ask1.20 x 0
Day's Range1.19 - 1.24
52 Week Range1.09 - 26.32
Volume224,187
Avg. Volume298,871
Market Cap155.364M
Beta10.18
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.35
  • GlobeNewswire4 days ago

    Emblem Announces $3 Million Strategic Equity Investment in Natura Naturals and 9,000 kg Supply Agreement over three years

    Emblem Corp. (EMC.V) (EMC-WT.V) (EMMBF) (“Emblem” or the “Company”), announced today that it is making a strategic equity investment (the “Equity Investment”) into Natura Naturals Inc. (“Natura”), a 662,000 square foot licensed greenhouse cultivator of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The companies have also signed a three-year cannabis supply agreement (the “Agreement”) to provide Emblem up to 3,000kg of high-quality cannabis flower per year from Natura’s Phase 1 cultivation facility.

  • ACCESSWIRE11 days ago

    Today's Research Reports on Emblem, OrganiGram, Oncolytics Biotech and Aptose Biosciences

    NEW YORK, NY / ACCESSWIRE / July 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • GlobeNewswire12 days ago

    Emblem inspires Canadians to Get Curious with the launch of new adult-use cannabis brand, Symbl

    Emblem Corp. (EMC.V) (EMC-WT.V) (“Emblem” or the "Company") today announced the launch of its first adult-use cannabis brand, Symbl. Leveraging Emblem’s existing brand strength in the medical market, Symbl was created to offer an equally thoughtful brand experience for those seeking cannabis for recreational use that fits within their productive lifestyle. Symbl was carefully crafted to be an approachable brand for Canadians as they navigate the new cannabis landscape come legalization on October 17, 2018.

  • GlobeNewswire17 days ago

    Emblem Completes Supply Agreement with Alberta Gaming, Liquor & Cannabis Commission (AGLC)

    Emblem Corp. (EMC.V) (EMC-WT.V) (“Emblem” or the "Company") is pleased to announce that its wholly owned subsidiary, Emblem Cannabis Corporation, one of Canada’s leading licensed producers, has completed an agreement with the Alberta Gaming, Liquor & Cannabis Commission (“AGLC”) to supply the province with high quality cannabis products. “Emblem is excited to have been selected to bring our adult-use products to Alberta’s recreational cannabis market upon legalization on October 17, 2018.

  • GlobeNewswirelast month

    Emblem to Launch Emblem Germany in Joint Venture with Acnos Pharma

    TORONTO, June 20, 2018-- Emblem Corp., is pleased to announce that its Board of Directors has approved the Company’ s formation of a joint venture under the name“ Emblem Germany” with German pharmaceutical ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Centric Health, Emblem, OrganiGram and Acerus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • GlobeNewswire2 months ago

    CORRECTING and REPLACING – Canntab Brings Pharma Standards to Medical Cannabis -- CFN Media

    In a release issued yesterday under the same headline by CFN Media, please be advised that a quote has been removed from the first paragraph. Additionally, the stock exchange for Emblem Corp. in the ninth paragraph should be TSX-V rather CSE, and the reference in that same paragraph to "five projects" should simply read "projects". The corrected release follows. CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering CannTab Therapeutics Inc. (PILL.CN) (PILL.CN) (PILL.CN) and its plan to make medical cannabis more reliable with its proprietary, patent-pending, extended-release tablets that offer a reliable and uniform dosage over several hours.

  • GlobeNewswire2 months ago

    Emblem Corp. Reports 2018 First Quarter Results

    Strengthened team, new products, and key distribution partnerships driving demand. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.. TORONTO, May 29, 2018-- ...

  • GlobeNewswire2 months ago

    Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation

    Emblem Corp. (EMC.V) (EMC-WT.V) (“Emblem” or the "Company") and Canntab Therapeutics Limited (CSE:PILL) (“Canntab”) are pleased to announce the receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the “Sustained Release Product” or the “Product”), which are the proprietary products conceived by Canntab representing significant progress in Emblem and Canntab’s partnership to develop long-acting cannabis formulations. “Product innovation, new formulations and dosage forms are critical pillars in Emblem’s competitive strength and growth strategy. Our licence agreement with Canntab is an important step in this direction. “We are thrilled that Health Canada has approved the research and development phase of our partnership with Canntab.

  • GlobeNewswire2 months ago

    Emblem Announces Settlement With Dissenting Shareholder

    Emblem Corp. (EMC.V) (EMC.WT) ("Emblem" or the "Corporation") announces that it has agreed to issue an aggregate of 482,758 common shares in the capital of Emblem (the “Common Shares”) to a former shareholder (the "Dissenting Shareholder") of Emblem’s predecessor KindCann Holdings Limited (“KindCann”). The Common Shares will be issued in settlement of statutory rights of dissent exercised by the Dissenting Shareholder in 2015 in respect of 2,000,000 Class A preferred shares of KindCann held by the Dissenting Shareholder. The Dissenting Shareholder exercised the statutory rights of dissent in connection with the amendment of KindCann’s articles to amend the share conditions attached to KindCann’s Class A preferred shares to provide KindCann’s board of directors with the discretion to pay the annual cash dividend afforded to the Class A preferred shares through the issuance of KindCann common shares.

  • GlobeNewswire2 months ago

    Emblem enters into Advisory Agreement with e.vestor Communications Inc.

    Emblem Corp. (EMC.V) (EMC-WT.V) ("Emblem" or the "Corporation") is pleased to announce the appointment of e.vestor Communications Inc. (“EVC”) as the Corporation’s capital markets and investor relations advisor through EVC’s principal, Cory Pala. EVC’s mandate will focus on providing capital markets guidance and support for Emblem through coordinated efforts to navigate the capital markets and support the Corporation’s continued listing on the Exchange. As consideration for the Services, the Corporation shall pay EVC a monthly fee of $10,000 to be paid out monthly.

  • GlobeNewswire3 months ago

    Emblem Announces Appointment of Dan Milliard to its Board of Directors

    Emblem Corp. (EMC.V) (EMC-WT.V) ("Emblem" or the "Corporation") announces that the board of directors has appointed Dan Milliard to Emblem’s board of directors replacing Mr. Lorne Gertner who resigned in April 2018. “Dan has extensive board experience (as a Chartered Director), public markets experience, and business leadership experience. He will be invaluable to our Board, management team and shareholders as we enter the next phase of our growth strategy,” added Dean. In connection with the appointment, subject to receipt of the TSX Venture Exchange’s approval of Mr. Milliard’s appointment, the Corporation has approved the granting of 250,000 incentive stock options (the “Options”) to Mr. Milliard.

  • GlobeNewswire3 months ago

    Emblem Announces 2017 Financial Results

    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.. TORONTO, April 27, 2018-- Emblem Corp., today reported its results for the fiscal year ended December ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Eyecarrot Innovations, Antibe Therapeutics, Emblem and Theralase Technologies

    NEW YORK, NY / ACCESSWIRE / April 20, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group3 months ago

    Canadian Cannabis Retailer Fire & Flower Secures 3-Year Preferred Supplier Agreement with Emblem

    Canadian Cannabis Retailer Fire & Flower Secures 3-Year Preferred Supplier Agreement with Emblem

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Emblem, 3D Signatures, ABcann Global and Theralase Technologies Inc.

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...